Viewing Study NCT07241793

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:18 AM
Ignite Modification Date: 2026-06-26 @ 4:05 AM
Study NCT ID: NCT07241793
Status: RECRUITING
Last Update Posted: 2025-12-18
First Post: 2025-09-24
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
Sponsor: Sun Yat-sen University
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Urothelial Carcinoma View
None Advanced Urothelial Carcinoma View
None Urothelial Carcinoma Recurrent View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Urothelial carcinoma View
None Antibody-Drug Conjugate View
None immune checkpoint inhibitor View